Our findings reveal that pharmacological inhibition of FAK in combination with RAF/MEK inhibition significantly suppresses melanoma growth, reduces the development of metastases in preclinical mouse models, and prolongs survival in mice with existing brain metastases. This evidence concerns the gene MAP2K7 and melanoma.